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The aim of the study is identification of correlations
between the serum concentrations of iron and the risk of
breast cancer among female BRCA1 mutations carriers
and unselected breast cancer patients.
The first group (99 triplet) selected for the trial were
Polish women, positive for at least one of three founder
mutations in BRCA1 gene dominating in Poland
(5382insC, C61G, 4153delA). Serum was collected at the
time of breast cancer diagnosis. Persons with detected
tumor were considered as cases and the others were con-
sidered as controls. One case and two controls were paired
regarding many criteria (e.g. age, family cancer history,
cigarettes smoking, adnexectomy status ) to achieve the
maximum of similarity between them.
The subjects of the second group (28 triplet) selected
for the trial were Polish women, positive for at least one
of three founder mutations in BRCA1 gene. Serum was
collected 1-2 years before breast cancer diagnosis. One
case and two controls were matched for year of birth,
past history of cancer, adnexectomy status and cigarettes
smoking to achieve the maximum of similarity between
them.
The subjects of the third group were unselected cancer
for the trial were Polish women. Serum was collected dur-
ing breast cancer diagnosis before treatment. One case
and one control were matched for year of birth (+/- 3
years), number and location of cancer among Iº relatives,
smoking-the number of pack years (+/- 10%), adnexect-
omy status, CHEK2 mutation.
The proportion of cases and control in the first quartile
was taken as a reference to calculate the odds ratio, confi-
dence interval and p-value of the multivariate conditional
logistic regression.
The iron was quantitatively measured by ICP-MS
(Inductively Coupled Plasma Mass Spectrometry),
(model Elan DRC-e 6100 th, PerkinElmer).
This study shows that concentration levels of iron in
blood serum are a strong factors associated with an
additionally increased risk of breast cancer among
BRCA1 mutation carriers and unselected breast cancer
patients.
For iron concentration in BRCA1 carriers (serum col-
lected at the time of breast cancer diagnosis) all quar-
tiles above the first one had a decreased risk of breast
cancer. The results are shown in Table 1.
For iron concentration in BRCA1 carriers (serum col-
lected 1-2 years before breast cancer diagnosis) the last
quartile had a decreased risk of breast cancer. The
results are shown in Table 2.
Individuals classified in the III and IV quartile had
lower risk of breast cancer however results were statisti-
cally insignificant.
The strongest result and lowest cancer risk was for Fe
> 1350 μg/l (OR= 0,289, p= 0,0426)
For iron concentration in unselected breast cancer
patients (serum was collected during breast cancer diag-
nosis before treatment) all quartiles were statistically
insignificant. The results are shown in Table 3.
Individuals classified in the III quartile had lower risk
of breast cancer however results were statistically
insignificant.
The strongest result and lowest cancer risk was for Fe
> 1000 μg/l (OR= 0,6698, p= 0,25554).
For iron concentration in unselected breast cancer
patients (serum was collected during breast cancer diag-
nosis before treatment) before 55 years old, third quar-
tile had a decreased risk of breast cancer. The results
are shown in Table 4.
Individuals classified in the III quartile had lower risk
of breast cancer (OR=0,248, p=0,019);
The strongest result and lowest cancer risk was for Fe
concentration higher than 987 μg/l (III quartile) ; max
1285 μg/l (III quartile)
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Table 1 Association between Fe serum concentration and
risk of breast cancer in BRCA 1 carriers (serum collected
at the time of breast cancer diagnosis).
Fe (µg/l) Cases (n=99) Controls (n=198) OR p-value
370,95 – 977,64 34 (34,3%) 40 (20,2%) 1,000 -
977,64 – 1262,78 24 (24,2 %) 50 (25,3%) 0,565 0.01229
1262,78 – 1571,11 24 (24,2%) 50 (25,3%) 0,565 0.13885
1571,11 - 4756,15 17 (17,17%) 58 (29,3%) 0,345 0.00823
Table 2 Association between Fe serum concentration and
risk of breast cancer in BRCA 1 carriers (serum collected
1-2 years before breast cancer diagnosis).
Fe (µg/l) Cases (n=27) Controls (n=56)
313,90 – 945,79 9 (33,3%) 12 (21,4%)
954,79 – 1157,15 9 (33,3%) 12 (21,4%)
1158,32 – 1437,54 5 (18,5%) 16 (28,6%)
1460,00 – 2193,10 4 (14,8%) 16 (28,6%)
Table 4 Association between Fe serum concentration and
risk of cancer in group of patients < 55 years old.
Fe (µg/l) Cases (n=59) Controls (n=62)
127,58 – 725,31 19 (32,2%) 11 (17,7%)
752,60 – 987,19 17 (28,8%) 13 (21,0%)
987,19 – 1285,18 9 (15,3%) 21 (33,9%)
1294,72 – 2584,76 14 (23,7%) 17 (27,4%)
Table 3 Association between Fe serum concentration and
risk of breast cancer
Fe (µg/l) Cases (n=151) Controls (n=151)
86,47 – 813,58 43 (28,47%) 32 (21,19%)
813,92 – 992,11 40 (26,49%) 35 (23,18%)
993,06 – 1265,75 35 (23,18%) 41 (27,15%)
1268,27 – 3676,38 33 (21,85%) 43 (28,48%)
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